Quanterix Valuation Multiples

Quanterix is valued at $152M as of October 2026, a 0.6x revenue multiple. In the last 12 months, Quanterix revenue was $143M and Quanterix EBITDA was ($68M).

Quanterix Overview

About Quanterix

Quanterix Corp is a life sciences company that focuses on developing an ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The Simoa bead-based and planar array platforms designed by the company enable customers to reliably detect protein biomarkers in low concentrations in blood, serum, and other fluids that are undetectable using conventional, analog immunoassay technologies. Its products include Simoa, Assay Kits, LDTs & Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, Instruments, HD-X Automated Immunoassay Analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, Simoa Accelerator Laboratory and others. Geographically, It operates in North America, EMEA and Asia Pacific.


Founded

2007

HQ

United States

Employees

136

Financials (LTM)

Revenue: $143M
EBITDA: ($68M)

EV

$92M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Quanterix Financials

Quanterix reported last 12-month revenue of $143M and negative EBITDA of ($68M).

In the same LTM period, Quanterix generated $63M in gross profit, ($68M) in EBITDA losses, and had net loss of ($107M).

Revenue (LTM)


Quanterix P&L

In the most recent fiscal year, Quanterix reported revenue of $139M and EBITDA of ($102M).

Quanterix is unprofitable as of last fiscal year, with gross margin of 47%, EBITDA margin of (74%), and net margin of (77%).

See analyst estimates for Quanterix
LTMLast FY202320242025202620272028
Revenue$143M$139M$121M$135M$139M
Gross Profit$63M$65M$69M$81M$65M
Gross Margin44%47%57%60%47%
EBITDA($68M)($102M)($40M)($44M)($102M)
EBITDA Margin(48%)(74%)(33%)(33%)(74%)
EBIT Margin(78%)(79%)(40%)(39%)(79%)
Net Profit($107M)($107M)($32M)($39M)($107M)
Net Margin(75%)(77%)(27%)(28%)(77%)
Net Debt-$7M---

Financial data powered by Morningstar, Inc.

Quanterix Stock Performance

Quanterix has current market cap of $152M, and enterprise value of $92M.

Market Cap Evolution


Quanterix's stock price is $3.21.

Quanterix share price decreased by 13.5% in the last 30 days, and by 39.6% in the last year.

Quanterix has an EPS (earnings per share) of $-2.27.

See more trading valuation data for Quanterix
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$92M$152M-3.3%-13.5%-7.7%-39.6%$-2.27

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Quanterix Valuation Multiples

Quanterix trades at 0.6x EV/Revenue multiple, and (1.3x) EV/EBITDA.

See NTM and 2027E valuation multiples for Quanterix

EV / Revenue (LTM)


Quanterix Financial Valuation Multiples

As of October 9, 2026, Quanterix has market cap of $152M and EV of $92M.

Quanterix has a P/E ratio of (1.4x).

LTMLast FY202320242025202620272028
EV/Revenue0.6x0.7x0.8x0.7x0.7x
EV/EBITDA(1.3x)(0.9x)(2.3x)(2.1x)(0.9x)
EV/EBIT(0.8x)(0.8x)(1.9x)(1.7x)(0.8x)
EV/Gross Profit1.5x1.4x1.3x1.1x1.4x
P/E(1.4x)(1.4x)(4.7x)(3.9x)(1.4x)
EV/FCF-(1.1x)(4.0x)(2.4x)(1.1x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Quanterix Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Quanterix Margins & Growth Rates

Quanterix grew revenue by 4% but EBITDA decreased by 26% in the last fiscal year.

In the most recent fiscal year, Quanterix reported gross margin of 47%, EBITDA margin of (74%), and net margin of (77%).

See estimated margins and future growth rates for Quanterix

Quanterix Margins

Last FY202420252026202720282029
Gross Margin47%60%47%44%
EBITDA Margin(74%)(33%)(74%)(52%)
EBIT Margin(79%)(39%)(79%)(77%)
Net Margin(77%)(28%)(77%)(74%)
FCF Margin(58%)(28%)(58%)-

Quanterix Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth4%12%2%4%
Gross Profit Growth(3%)17%(20%)(3%)
EBITDA Growth(26%)11%130%(26%)
EBIT Growth1%9%109%1%
Net Profit Growth(1%)19%178%(1%)
FCF Growth-70%107%-

Data powered by FactSet, Inc. and Morningstar, Inc.

Quanterix Operational KPIs

Quanterix's revenue per employee in the last FY averaged $1.0M, while opex per employee averaged $1.4M for the same period.

Quanterix's Rule of 40 is (49%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Quanterix's Rule of X is (43%) (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Quanterix
LTMLast FY202320242025202620272028
Rule of 40(39%)(49%)---
Bessemer Rule of X(27%)(43%)---
Revenue per Employee-$1.0M---
Opex per Employee-$1.4M---
G&A Expenses to Revenue-100%78%77%100%
R&D Expenses to Revenue23%26%21%23%26%
Opex to Revenue-137%97%99%137%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Quanterix Competitors

Quanterix competitors include Medinice, BICO Group, Paxman, Inogen, Neuronetics, JETEMA Co., Huons Co, Nyxoah, Owlet and EKF Diagnostics.

Most Quanterix public comparables operate across Medical Devices, DeepTech and HealthTech.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
Medinice-($2M)-4.5x(90.2x)5.2x
BICO Group$150M($130M)1.1x1.0x(1.2x)19.0x
Paxman$31M$3M4.6x3.6x50.9x23.8x
Inogen$349M($7M)0.2x0.2x(9.5x)18.5x
Neuronetics$149M($28M)1.6x1.5x(8.3x)(17.8x)
JETEMA Co.$57M$8M4.1x-28.2x-
Huons Co$463M$60M0.6x-4.5x-
Nyxoah$11M($95M)7.7x2.5x(0.9x)(1.1x)

This data is available for Pro users. Sign up to see all Quanterix competitors and their valuation data.

Start Free Trial

Quanterix VC Funding History

Before going public, Quanterix raised $55M in total equity funding, across 2 rounds.


Quanterix Funding Rounds

DateStageInvestorsRaisedValuationRev. MultipleDeal Summary
Aug-17Series DT. Rowe Price$9M-Quanterix, a developer of an ultra-sensitive diagnostic platform digitizing biomarker analysis for precision health, completed an $8.5 million private placement on August 3, 2017, led by funds advised by T. Rowe Price Associates. This funding followed its Series D round of $46 million raised in March 2016 and was intended to develop new instruments, expand the assay menu, and meet global demand across therapeutic markets including oncology, neurology, cardiology, inflammation, and infectious disease. The company, founded in 2007 and based in Lexington, Massachusetts, had raised approximately $55 million prior to this round to advance its global reach.
Mar-16Series DTrinitas Capital; Tufts University; ARCH Overage Fund; Hercules Capital; Bain Capital Ventures; Cormorant Asset Management; ARCH Venture Partners$46M--

Acquisitions by Quanterix

Quanterix has acquired 3 companies to date.

Last acquisition by Quanterix was on January 10th 2025. Quanterix acquired Akoya Biosciences for $286M (EV/Revenue multiple available to Pro users).

See M&A valuation multiples

Latest Acquisitions by Quanterix

Akoya Biosciences
Emission iNC
UmanDiagnostics
Description
Akoya Biosciences is a spatial-biology instruments and software business founded in 2015 and based in Marlborough, Massachusetts. It developed the PhenoCycler and PhenoImager platforms for high-parameter imaging and analysis of tissue at single-cell and spatial resolution. Its product portfolio includes imaging instruments, assay kits, reagents and software used in discovery, translational research and clinical-development workflows. Pharmaceutical companies, academic laboratories and clinical researchers use the systems in immuno-oncology, neuroscience, autoimmune disease and other areas requiring multiplex tissue analysis. Akoya generated revenue from instrument sales, consumables, software and laboratory services. The company went public in 2021 and completed a merger with Quanterix in July 2025. Akoya's spatial-biology products now form part of Quanterix's broader biomarker and research-tools platform.
Emission iNC is a Boston-based biotech firm providing multiplex assay instruments and reagents for high-throughput protein analysis, enabling labs to run assays at lower costs with higher sensitivity for research in proteomics and diagnostics.
UmanDiagnostics manufactures neurofilament light chain ELISA kits and antibodies for biomarker research in ALS and Alzheimer's. Umea-based since 1990, the Swedish firm supplies 1,000+ labs worldwide, with kits detecting Nf-L at 30 pg/mL sensitivity used in Roche and Biogen trials.
HQ CountryUnited StatesUnited StatesSweden
HQ City
Marlborough, MA
Austin, TX
Umeå
Deal Date10 Jan 202517 Dec 202426 Jun 2019
Valuation$286M$70M$23M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Quanterix acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Quanterix

When was Quanterix founded?Quanterix was founded in 2007.
Where is Quanterix headquartered?Quanterix is headquartered in United States.
How many employees does Quanterix have?As of today, Quanterix has over 136 employees.
Who is the CEO of Quanterix?Quanterix's CEO is Everett V. Cunningham.
Is Quanterix publicly listed?Yes, Quanterix is a public company listed on Nasdaq.
What is the stock symbol of Quanterix?Quanterix trades under QTRX ticker.
When did Quanterix go public?Quanterix went public in 2017.
Who are competitors of Quanterix?Quanterix main competitors include Medinice, BICO Group, Paxman, Inogen, Neuronetics, JETEMA Co., Huons Co, Nyxoah, Owlet, EKF Diagnostics.
What is the current market cap of Quanterix?Quanterix's current market cap is $152M.
What is the current revenue of Quanterix?Quanterix's last 12 months revenue is $143M.
What is the current revenue growth of Quanterix?Quanterix revenue growth (NTM/LTM) is 8%.
What is the current EV/Revenue multiple of Quanterix?Current revenue multiple of Quanterix is 0.6x.
Is Quanterix profitable?No, Quanterix is not profitable.
What is the current EBITDA of Quanterix?Quanterix has negative EBITDA and is not profitable.
What is Quanterix's EBITDA margin?Quanterix's last 12 months EBITDA margin is (48%).
What is the current EV/EBITDA multiple of Quanterix?Current EBITDA multiple of Quanterix is (1.3x).
How many companies Quanterix has acquired to date?As of October 2026, Quanterix has acquired 3 companies.
What was the largest acquisition by Quanterix?$286M acquisition of Akoya Biosciences on 10th January 2025 was the largest M&A Quanterix has done to date.
What companies Quanterix acquired?Quanterix acquired Akoya Biosciences, Emission iNC, and UmanDiagnostics.
In how many companies Quanterix has invested to date?Quanterix hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Quanterix

Lists including Quanterix

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial